Summary of Study ST002193

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001397. The data can be accessed directly via it's Project DOI: 10.21228/M84T4X This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002193
Study TitleThe effects of obesity microbiota produced metabolites on colorectal carcinogenesis in murine models
Study SummaryObesity is a risk factor for colorectal cancer (CRC). We aim to study the effects and mechanisms of gut microbiota of obese subjects in contributing to CRC progression. Conventional AOM-treated and ApcMin/+ mice receiving feces from obese individuals showed significantly increased colon tumor formation compared with those receiving feces from control subjects. AOM-treated mice receiving feces from obese (OB-M) exhibited microbiota dysbiosis with enriched potential pathobionts Erysipelotrichaceae bacterium GAM147, Turicibacter sp. H121, Mucinivorans hirudinis, and depleted symbionts Bacteroides vulgatus, Faecalibaculum rodentium, Bifidobacterium spp. and Lactobacillus delbrueckii. The OB-M group also showed altered gut metabolites including elevated phenylacetic acid, and depleted genipin. Moreover, OB-M group showed impaired intestinal barrier function and significant upregulation of pro-inflammatory cytokines and activation of oncogenic Wnt signaling pathway. In conclusion, gut microbiota from obese individuals promotes colorectal carcinogenesis. Microbiota modulation in obese individuals may provide new insight into obesity-driven CRC prevention and therapy.
Institute
The Chinese University of Hong Kong
Last NameKang
First NameXing
AddressRm806, Li Ka Shing Medical Science Building, PWH, Shatin, Hong Kong
Emailkangxing92@163.com
Phone93760832
Submit Date2022-05-18
Raw Data AvailableYes
Raw Data File Type(s)mzXML
Analysis Type DetailLC-MS
Release Date2023-05-18
Release Version1
Xing Kang Xing Kang
https://dx.doi.org/10.21228/M84T4X
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Combined analysis:

Analysis ID AN003589 AN003590
Analysis type MS MS
Chromatography type Reversed phase Reversed phase
Chromatography system Thermo Q Exactive HF-X Thermo Q Exactive HF-X
Column UPLC BEH Amide column (2.1mm × 100mm, 1.7μm) UPLC BEH Amide column (2.1mm × 100mm, 1.7μm)
MS Type ESI ESI
MS instrument type Orbitrap Orbitrap
MS instrument name Thermo Q Exactive HF-X Orbitrap Thermo Q Exactive HF-X Orbitrap
Ion Mode POSITIVE NEGATIVE
Units m/z m/z
  logo